Patents Assigned to LYVGEN BIOPHARMA (SUZHOU) CO., LTD.
  • ANTI-CD40 BINDING MOLECULES HAVING ENGINEERED FC DOMAINS AND THERAPEUTIC USES THEREOF
    Publication number: 20220081487
    Abstract: The disclosure provides CD40-binding molecules comprising engineered human IgG domains, for example, human IgG1, IgG2, and IgG4 variants having mutations in the hinge domain, which exhibit altered binding activity to one or more Fc? receptors. Also described herein are methods for selectively activating or inhibiting immune responses in a subject using the CD40-binding molecules.
    Type: Application
    Filed: November 29, 2021
    Publication date: March 17, 2022
    Applicants: LYVGEN BIOPHARMA (SUZHOU) CO., LTD.
    Inventors: Jieyi WANG, Yi WU
  • Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof
    Patent number: 11186648
    Abstract: The disclosure provides CD40-binding molecules comprising engineered human IgG domains, for example, human IgG1, IgG2, and IgG4 variants having mutations in the hinge domain, which exhibit altered binding activity to one or more Fc? receptors. Also described herein are methods for selectively activating or inhibiting immune responses in a subject using the CD40-binding molecules.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: November 30, 2021
    Assignees: LYVGEN BIOPHARMA CO., LTD., LYVGEN BIOPHARMA (SUZHOU) CO., LTD.
    Inventors: Jieyi Wang, Yi Wu
  • ANTI-CD40 BINDING MOLECULES HAVING ENGINEERED FC DOMAINS AND THERAPEUTIC USES THEREOF
    Publication number: 20210301029
    Abstract: The disclosure provides CD40-binding molecules comprising engineered human IgG domains, for example, human IgG1, IgG2, and IgG4 variants having mutations in the hinge domain, which exhibit altered binding activity to one or more Fc? receptors. Also described herein are methods for selectively activating or inhibiting immune responses in a subject using the CD40-binding molecules.
    Type: Application
    Filed: March 19, 2021
    Publication date: September 30, 2021
    Applicants: LYVGEN BIOPHARMA CO., LTD., LYVGEN BIOPHARMA (SUZHOU) CO., LTD.
    Inventors: Jieyi WANG, Yi WU
  • HUMANIZED ANTI-CD137 ANTIBODIES AND USES THEREOF
    Publication number: 20210246218
    Abstract: Disclosed herein are humanized anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.
    Type: Application
    Filed: March 19, 2021
    Publication date: August 12, 2021
    Applicants: LYVGEN BIOPHARMA (SUZHOU) CO., LTD.
    Inventors: Jieyi WANG, Yi WU